Bilfinger SE (BFLBF) Q2 2025 Earnings Call Transcript

Bilfinger SE reported a strong Q2 2025, achieving a record 18% surge in orders received to nearly EUR 1.8 billion and a 4% organic revenue increase to EUR 1.35 billion. The adjusted EBITA margin expanded by 90 basis points to 5.5%, while cash flow more than doubled. The company confirmed its full-year guidance, targeting the midpoint, supported by a robust order backlog that provides 85-90% coverage for 2025 revenue. Growth was notably driven by strong performance in pharma/biopharma and oil & gas, offsetting regional challenges in the chemicals sector, with management attributing margin expansion to operational excellence and strategic positioning in a volatile market. Bilfinger also highlighted its approved Net Zero targets and ongoing pursuit of strategic M&A.

Analysis

Bilfinger SE (BFLBF) delivered a robust Q2 2025 performance, underscored by a record order intake that surged 18% (16% organically) to nearly €1.8 billion, providing significant forward visibility. Revenue grew 4% to €1.35 billion, while the adjusted EBITA margin expanded by a notable 90 basis points year-over-year to 5.5%, demonstrating successful execution on operational efficiency and derisking initiatives. This margin improvement was achieved despite flat SG&A costs in absolute terms, which included the integration of recent acquisitions. The company's free cash flow more than doubled, reflecting disciplined working capital management. Growth was driven by strength in the Pharma/Biopharma and Oil & Gas sectors, the latter benefiting from investment revivals in the Middle East and the US, which effectively offset persistent softness in the European chemicals market, particularly in Germany. Management's confidence is reflected in the confirmation of its full-year 2025 guidance, with an explicit emphasis on targeting the midpoint of all ranges. The order backlog now covers 85-90% of planned 2025 revenue, lending high credibility to this outlook. A key risk to monitor is a newly filed legal complaint against a US subsidiary, though it is in a very early stage with no financial quantum specified. The company also highlighted its approved net-zero targets and has scheduled a Capital Markets Day for December 2nd to announce new mid-term targets through 2030.

Key Decisions for Investors

• The record order intake and strong backlog, which covers 85-90% of 2025 revenue targets, provides a high degree of operational stability, suggesting investors can maintain a constructive stance despite macroeconomic volatility.
• Monitor the continued EBITA margin progression, as management's ability to drive profitability through operational efficiencies and a favorable mix shift towards Energy and Oil & Gas is a core component of the investment thesis.
• Investors should note the upcoming Capital Markets Day on December 2nd as a key catalyst, where new long-term targets to 2030 will be announced, offering potential for a re-rating based on the future strategic direction.
• While the financial impact is currently unquantifiable, the legal complaint filed against a US subsidiary introduces a new risk factor that requires monitoring for any future developments or potential provisions.
• Given the confirmed guidance and strong cash flow generation, consider the company's M&A strategy, particularly potential larger acquisitions in the US or Middle East, as a future driver of growth and shareholder value.